Cost keeps French away from medicines
This article was originally published in Scrip
The polling company IPSOS has found that 18% of French people have refrained from buying a medicine for reasons of cost. The survey on belt-tightening in the current economic downturn in France also found 39% had chosen not to seek medical help or had delayed seeking it, also for reasons of cost. In households with net incomes of less than €1,200 per month, this proportion rises to 52%. Dental and optical treatments were those that French people put off most frequently.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.